Cost evaluation of antibody production processes in different operation modes

Chemical Engineering Science

Volumn 141, Issue , 2016, Pages 63-74

  Klutz, Stephan ^a   Holtmann, Laura ^a   Lobedann, Martin ^a   Schembecker, Gerhard ^b  

^a Building W 32   (Germany)

^b TU DORTMUND UNIVERSITY   (Germany)

Author keywords

Antibodies; Bioprocess engineering; Continuous processing; Cost evaluation; Platform process

Indexed keywords

ANTIBODIES; COST ENGINEERING; COST ESTIMATING; COSTS; FERMENTATION;

ANTIBODY PRODUCTION; BIOPROCESS ENGINEERING; CHROMATOGRAPHY RESIN; CONTINUOUS PROCESSING; COST EVALUATIONS; FERMENTATION MEDIUM; PLATFORM PROCESS; PRODUCTION CAPACITY;

BATCH DATA PROCESSING;

EID: 84959441055     PISSN: 00092509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ces.2015.10.029     Document Type: Article

References (23)

1. Bisschops M., Frick L., Fulton S., Ransohoff T. Single-use, continuous-countercurrent, multicolumn chromatography. Bioprocess Int. 2009, 7(S5):18-23.
2. Brod H., Vester A., Kauling J. Möglichkeiten und Grenzen von Disposable - Technologien in biopharmazeutischen Verfahren. Chem. Ing. Tech. 2012, 84(5):633-645.
3. Challener C.A. Monoclonal antibodies key to unlocking the biosimilars market. The approval and acceptance of monoclonal antibody biosimilars is necessary if the biosimilars market is to experience real growth. BioPharm Int. 2014, 27(4):20-23.
4. Farid S.S., Washbrook J., Titchener-Hooker N.J. Decision-support tool for assessing biomanufacturing strategies under uncertainty: stainless steel versus disposable equipment for clinical trial material preparation. Biotechnol. Progr. 2005, 21(2):486-497.
5. Hammerschmidt N., Tscheliessnig A., Sommer R., Helk B., Jungbauer A. Economics of recombinant antibody production processes at various scales: industry-standard compared to continuous precipitation. Biotechnol. J. 2014, 9(6):766-775.
6. Jagschies G., Gronberg A., Bjorkman T., Johansson H.J., Lacki K.M. Technical and economical evluation of downstream processing options for monoclonal antibody (Mab) production. Updated downstream processes can pave the way for increased productivity, now and in the future. BioPharm Int. 2006, (Suppl. 19):10-19. (June).
7. Kelley B. Industrialization of mAb production technology. The bioprocessing industry at a crossroads. mAbs 2009, 1(5):443-452.
8. Klutz S., Kurt S.K., Lobedann M., Kockmann N. Narrow residence time distribution in tubular reactor concept for Reynolds number range 10-100. Chem. Eng. Res. Des. 2015, 95:22-33.
9. Klutz S., Magnus J., Lobedann M., Schwan P., Maiser B., Niklas J., Temming M., Schembecker G. Developing the biofacility of the future based on continuous processing and single-use technology. J. Biotechnol. 2015, 213:120-130.
10. Konstantinov K.B., Goudar C., Ng M., Meneses R., Thrift J., Chuppa S., Matanguihan C., Micheals J., Naveh D. The "push-to-low" approach for optimization of high-density perfusion cultures of animal cells. Adv. Biochem. Eng./Biotechnol. 2006, 101:75-98.
11. Levine H.L., Lilja J.E., Stock R., Hummel H., Jones S.D. Efficient, flexible facilities for the 21st century. Bioprocess Int. 2012, 10(S11):20-30.
12. Lim A.C., Washbrook J., Titchener-Hooker N.J., Farid S.S. A computer-aided approach to compare the production economics of fed-batch and perfusion culture under uncertainty. Biotechnol. Bioeng. 2006, 93(4):687-697.
13. Nfor B.K., Ahamed T., van Dedem G.W.K., Verhaert P.D.E.M., van der Wielen L.A.M., Eppink M.H.M., van de Sandt E.J.A.X., Ottens M. Model-based rational methodology for protein purification process synthesis. Chem. Eng. Sci. 2013, 89:185-195.
14. Nfor B.K., Zuluaga D.S., Verheijen P.J.T., PDEM Verhaert, van der Wielen L.A.M., Ottens M. Model-based rational strategy for chromatographic resin selection. Biotechnol. Progr. 2011, 27(6):1629-1643.
15. Novais J.L., Titchener-Hooker N.J., Hoare M. Economic comparison between conventional and disposables-based technology for the production of biopharmaceuticals. Biotechnol. Bioeng. 2001, 75(2):143-153.
16. Pollock J., Ho S.V., Farid S.S. Fed-batch and perfusion culture processes: economic, environmental, and operational feasibility under uncertainty. Biotechnol. Bioeng. 2013, 110(1):206-219.
17. Simaria A.S., Turner R., Farid S.S. A multi-level meta-heuristic algorithm for the optimisation of antibody purification processes. Biochem. Eng. J. 2012, 69:144-154.
18. Sommerfeld S., Strube J. Challenges in biotechnology production - generic processes and process optimization for monoclonal antibodies. Chem. Eng. Process. Process Intensif. 2005, 44(10):1123-1137.
19. Stonier A., Simaria A.S., Smith M., Farid S.S. Decisional tool to assess current and future process robustness in an antibody purification facility. Biotechnol. Progr. 2012, 28(4):1019-1028.
20. Tufts Center for the Study of Drug Development. Outlook 2013. (accessed 21.05.14). http://csdd.tufts.edu/files/uploads/Outlook-2013.pdf.
21. Varadaraju H., Schneiderman S., Zhang L., Fong H., Menkhaus T.J. Process and economic evaluation for monoclonal antibody purification using a membrane-only process. Biotechnol. Progr. 2011, 27(5):1297-1305.
22. Woods D.R. Rules of Thumb in Engineering Practice 2007, xix:458. Wiley-VCH, Weinheim, Chichester.
23. Wurm F.M. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 2004, 22(11):1393-1398.